Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SIG001 in Subjects With Advanced Solid Tumors.

NCT07486700 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT07486700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07486700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SIG001 in Subjects With Advanced Solid Tumors.
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
July 31, 2028
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplams